What Is MK-2866 50MG / ML | 60ML?
MK-2866 is also known by the names of ostarine and GTx-024. It belongs to the class selective androgen receptor modulator (SARM). It was initially developed by a pharmaceutical company, GTx. Inc, for conditions like muscle wasting and osteoporosis. Research shows that it increases muscle mass and growth, improves insulin sensitivity and prevents bone loss. It has also been shown to treat breast cancer. The research on ostarine is limited and it is classified as an investigational drug. Furthermore, it is banned by the World Anti-Doping Agency (WADA) as it has been shown to increase strength performance. At Pinnacle Peptides, MK-2866 for sale is exclusively available for research and experimentation.
Structure Of MK-2866 50MG / ML | 60ML
From Pubchem
IUPAC Name: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
Synonyms: ENOBOSARM, Ostarine, 841205-47-8, GTx-024
Molecular Formula: C19H14F3N3O3
Molecular Weight: 389.3 g/mol
CAS number: 841205-47-8
PubChem CID: 11326715
Mechanism Of MK-2866 50MG / ML | 60ML
Mk-2866 is an androgen receptor modulator that has been shown to only exert anabolic effects without targeting receptors in prostate tissues. It binds with androgen receptors in specific tissues such as muscles. This triggers the cascade of intracellular signaling, resulting in protein synthesis within muscle cells that promotes muscle growth and repair. Furthermore, ostarine has been shown to influence bone cells.
Pre-Clinical/Clinical Research
1. Stress Urinary Incontinence
Stress urinary incontinence is characterized by the involuntary leakage of urine due to weakened pelvic floor muscles. It has been shown that androgen receptors are abundantly present in the pelvic floor, and the drugs that modulate these receptors might prove useful for the treatment of stress urinary incontinence. Research on the ovariectomized mouse model found that Mk-2866 increased the pelvic floor muscle mass, which might translate into improved symptoms of urinary incontinence [1]. However, the drug couldn’t pass the phase II clinical trial conducted on postmenopausal women as it didn’t meet the primary endpoint [2].
2. Muscle Mass
Research suggests that muscle mass and physical function decline with advancing age due to hormonal changes in postmenopausal women. As a SARM, Mk-2866 might be able to restore or at least prevent a decrease in muscle function. In an ovariectomized rat study, a five-week ostarine treatment resulted in increased capillary density in the gastrocnemius and longissimus muscles compared to untreated rats, indicating improved health of muscle tissue [3].
Similarly, a study was conducted to explore the effects of ostarine on postmenopausal women and elderly men. Participants were randomly assigned to receive 0.1, 0.3, 1 mg, 3 mg ostarine, or a placebo for three months. The results demonstrated that Mk-2866 increases mass in a dose-dependent manner as it was found to enhance the body mass, with a 1.4 kg increase at a 3 mg dose compared to the placebo. Additionally, the patients who were treated with the drug exhibited improvements in the stair climbing test, reflecting improved physical performance in terms of both speed and power [4].
Cachexia is characterized by loss of skeletal muscles and strength. One study investigated the effect of ostarine on cachexia in cancer patients. Non-obese postmenopausal women and men, who lost 2% weight during cancer treatment, were enrolled in the study. The subjects were randomly administered either ostarine (1mg, 3mg) or a placebo for 113 days. The results indicated a significant increase in lean body mass in patients who took ostarine as compared to the control group [5].
3. Insulin Sensitivity
Results from a phase II trial conducted on postmenopausal women and elderly men found that 3mg enobosarm reduced fasting blood glucose (FBG) levels by 11% and insulin resistance by 26.8%. The antidiabetic effect of MK-2866 was more significant in prediabetic women who experienced a reduction in FBG by 17% and insulin resistance by 43% [6].
4. Bone Mineral Density
One study in a rat model of osteoporosis found that Mk-2866 treatment for 35 days resulted in increased bone mineral density and bone volume density [7]. Similarly, another study replicated similar results in ovariectomized rats. It found that ostarine treatment resulted in enhanced callus formation and increased callus density, initiating the process of bone healing [8].
5. Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer
Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer (AR+ TNBC) is linked with the overexpression of androgen receptors. Hence, drugs that target this receptor might show effectiveness for breast cancer treatment. Research shows that a combination of MK-2866 and pembrolizumab can improve clinical response by 25% with tolerable side effects [9].
Summary
MK-2866 is a selective androgen receptor modulator. It selectively targets androgen receptors in specific tissues and exhibits anabolic function. It has been shown to increase muscle mass, improve insulin sensitivity and treat AR+ TNMC. It is an investigation drug that has not been approved by the FDA yet. We don’t support its unwarranted use and offer MK-2866 for research and educational institutions. Only Mk-2866 if you are a qualified researcher.
References
- Ponnusamy, S., et al., Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice. J Cell Biochem, 2017. 118(3): p. 640-646.
- Writer, G. S. (2023, June 2). GTx’s Enobosarm Fails Phase II Trial in Stress Urinary Incontinence; Stock Plunges 90%+. GEN - Genetic Engineering and Biotechnology News.
- Roch, P.J., et al., Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model. Frontiers in Endocrinology, 2020. 11.
- Evans, W., et al., Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients. Journal of Clinical Oncology, 2007. 25(18_suppl): p. 9119-9119.
- Dobs, A.S., et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol, 2013. 14(4): p. 335-45.
- Dalton, J.T., et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle, 2011. 2(3): p. 153-161.
- Hoffmann, D.B., et al., Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism, 2019. 37(2): p. 243-255.
- Komrakova, M., et al., The Selective Androgen Receptor Modulator Ostarine Improves Bone Healing in Ovariectomized Rats. Calcified Tissue International, 2020. 106(2): p. 147-157.
- Yuan, Y., et al., A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer. The Oncologist, 2020. 26(2): p. 99-e217.
Certificate of Analysis (COA)
High Performance Liquid Chromatography (HPLC)
-
Fast deliveryI got what I was looking for. Thank you for the fast delivery.
Posted on
-
GreatPleasantly surprised by the quality of MK . Great.
Posted on
-
5 stars for everythingBrilliant. 5 stars for everything. Thanks
Posted on
-
Great shopping experienceGreat shopping experience. Thank you very much.
Posted on
-
Great stuff. 100% satisfied.Great stuff. 100% satisfied.
Posted on
-
Excellent MK-2866Irreplaceable.Shipment arrived on time.The item MK-2866
is excellent.Posted on
-
Great as alwaysEverything I order is always quality and shipping is always fast
Posted on
-
Fast!They have great customer service and immediate shipping.
Posted on
-
ThanksAs Always shipment was fast, Thanks.
Posted on
-
Awesome experience!Shipping was very fast and customer service was great! I will deffinately order from here in the future
Posted on